Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can prostate cancer be prevented?

Eric A Klein1

  • 1Section of Urologic Oncology, Glickman Urological Institute. kleine@ccf.org

Nature Clinical Practice. Urology
|February 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.

Cancer prevention research (Philadelphia, Pa.)·2025
Same author

Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Testosterone Replacement Therapy and Risk of COVID-19 and Effect of COVID-19 on Testosterone's Treatment Effect.

Journal of the Endocrine Society·2025
Same author

CpgD is a phosphoglycerate cytidylyltransferase required for ceramide diphosphoglycerate synthesis.

bioRxiv : the preprint server for biology·2025
Same author

A histidine-rich extension of the mitochondrial F<sub>0</sub> subunit ATP6 from the ice worm Mesenchytraeus solifugus increases ATP synthase activity in bacteria.

FEBS letters·2025
Same author

Low Baseline IsoPSA Index is Associated With a Prolonged Low Risk of Clinically Significant Prostate Cancer Diagnosis in Men With an Elevated PSA.

Urology·2025

Primary chemoprevention aims to reduce cancer incidence and mortality. Studies show finasteride and potentially selenium with vitamin E may prevent prostate cancer, but risks must be weighed.

Area of Science:

  • Oncology
  • Preventive Medicine
  • Molecular Biology

Background:

  • Prostate cancer is a significant health concern due to its high incidence, prevalence, and mortality.
  • Its long latency and known environmental risk factors make it a suitable target for chemoprevention.
  • Previous research, like the Prostate Cancer Prevention Trial (PCPT), has explored pharmaceutical interventions.

Purpose of the Study:

  • To evaluate the potential of chemopreventive agents in reducing prostate cancer incidence.
  • To assess the efficacy and risks associated with agents like finasteride, selenium, and vitamin E.
  • To inform the development of evidence-based strategies for prostate cancer primary prevention.

Main Methods:

  • Review of existing epidemiologic, molecular, and clinical evidence.

Related Experiment Videos

  • Analysis of data from large-scale prevention trials such as PCPT and SELECT (Selenium and Vitamin E Cancer Prevention Trial).
  • Assessment of risk-benefit profiles for chemopreventive agents.

    • Main Results:

    • Finasteride demonstrated efficacy in preventing prostate cancer but showed a potential increase in high-grade disease risk.
    • Evidence suggests selenium and vitamin E may also offer preventive benefits, currently under investigation in the SELECT trial.
    • The overall effectiveness of a preventive strategy depends on balancing potential benefits against agent-specific risks.

    Conclusions:

    • Chemoprevention holds promise for reducing prostate cancer burden.
    • Careful consideration of both efficacy and adverse events is crucial when selecting preventive agents.
    • Ongoing trials like SELECT are vital for establishing safe and effective prostate cancer prevention strategies.